P
PJP icon

&Partners’s Invesco Pharmaceuticals ETF PJP Stock Holding History

&Partners’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$517K Buy
4,985
+1,617
+48% +$171K ﹤0.01% 1675
2025
Q4 		$352K Buy
3,368
+5
+0.1% +$503 ﹤0.01% 1822
2025
Q3 		$311K Sell
3,363
-192
-5% -$16.8K ﹤0.01% 1728
2025
Q2 		$284K Sell
3,555
-4
-0.1% -$319 ﹤0.01% 1652
2025
Q1 		$300K Sell
3,559
-157
-4% -$13.4K ﹤0.01% 1412
2024
Q4 		$310K Sell
3,716
-7
-0.2% -$602 ﹤0.01% 1323
2024
Q3 		$324K Sell
3,723
-18
-0.5% -$1.54K 0.01% 1065
2024
Q2 		$308K Buy
+3,741
New +$297K 0.01% 706

Other funds holding PJP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAM
Peak Asset Management Louisville, Colorado $567M AUM 16.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CI
Cavalier Investments Alpharetta, Georgia $3.7B AUM 51.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

&Partners's PJP Position: Q1 2026 in Review

&Partners increased its Invesco Pharmaceuticals ETF (PJP) stake by 48% in Q1 2026, buying an estimated $171K and bringing the position to 4,985 shares worth $517K. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

&Partners first reported a position in PJP in Q2 2024 and has held it in 8 quarters since. 119 funds tracked by Wall St. Rank hold PJP as of Q1 2026.

  • &Partners held 4,985 shares of Invesco Pharmaceuticals ETF worth $517K as of Q1 2026.
  • &Partners bought 1,617 Invesco Pharmaceuticals ETF shares in Q1 2026, an estimated $171K.
  • Invesco Pharmaceuticals ETF made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1675 holding.
  • &Partners first reported a position in Invesco Pharmaceuticals ETF in Q2 2024 and has held it in 8 quarters since.
  • 119 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.